DRG Market Assessment reports

In This Underserved Arena, What Clinical Attributes Will Be Most Persuasive for Neurologists and Payers Regarding Novel Outpatient Rescue Therapies? Acute repetitive seizures (ARS)—also known…

What Attributes of Emerging Therapies Will Most Influence Both Physicians’ and Payers’ Decisions to Effectively Position These Biologics Against IV Belimumab? Systemic lupus erythematosus (…

TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of reports that examines current trends in the management of unresectable or metastatic malignant melanoma from the…

With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market? Affecting more than three million people in the major…

How Will the Rise in Antibiotic Resistance Shape the U.S. Prescribing and Reimbursement Environment for Novel Antibiotics? Although antibiotics from several drug classes are available to treat…

A Survey of Nephrologists and Interviews with Payers in the EU5 Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD)…

How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…

Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them? Renal anemia is one of the primary complications of chronic kidney disease (…

Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…

In a Market of Entrenched, Effective, and Mostly Generic Therapies, Where Do Physicians and Payers Identify Areas for Differentiation? The prevalence of Parkinson’s disease (PD) will approach…

How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL…

Compared with Current and Emerging Non-Insulin Therapies, Does Metformin’s Clinical Profile Justify Its Dominant Position in Recommended Treatment Guidelines? Affecting 30 million people in…